Literature DB >> 21733244

Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia.

Jeremy W Gawryluk1, Jun-Feng Wang, Ana C Andreazza, Li Shao, Lakshmi N Yatham, L Trevor Young.   

Abstract

Antioxidant defence systems have received increasing attention in the pathophysiology of psychiatric disorders, including: bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ). Recently, we reported decreased glutathione (GSH) levels in post-mortem prefrontal cortex from patients with BD, MDD, and SCZ. To explore this further, we evaluated the levels of two glutathione S-transferase (GST) isoforms via immunoblotting: GST Pi and GST Mu. GST Pi levels were not affected in any of the patients groups vs. controls. GST Mu levels were significantly decreased in patients with MDD and SCZ but not BD. Compared to controls, GST Mu levels were not different in BD patients who had been treated with mood stabilizers at the time of death but were significantly lower in those not taking mood stabilizers at the time of death. These data suggest that GST Mu may be a target for mood stabilizers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733244     DOI: 10.1017/S1461145711000617

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  33 in total

Review 1.  Antioxidants as antidepressants: fact or fiction?

Authors:  Giovanni Scapagnini; Sergio Davinelli; Filippo Drago; Antonino De Lorenzo; Giovannangelo Oriani
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

Review 2.  Animal models of bipolar mania: The past, present and future.

Authors:  R W Logan; C A McClung
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 3.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 4.  The glutathione system: a new drug target in neuroimmune disorders.

Authors:  Gerwyn Morris; George Anderson; Olivia Dean; Michael Berk; Piotr Galecki; Marta Martin-Subero; Michael Maes
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

Review 5.  [Oxidative stress in bipolar affective disorder].

Authors:  E Z Reininghaus; S Zelzer; B Reininghaus; N Lackner; A Birner; S A Bengesser; F T Fellendorf; H-P Kapfhammer; H Mangge
Journal:  Nervenarzt       Date:  2014-09       Impact factor: 1.214

6.  Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders.

Authors:  Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos
Journal:  Antioxid Redox Signal       Date:  2019-02-01       Impact factor: 8.401

7.  N-Acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats.

Authors:  Marisa Möller; Jan L Du Preez; Francois P Viljoen; Michael Berk; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2013-09-03       Impact factor: 3.584

8.  Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines.

Authors:  Ivana Perić; Andrijana Stanisavljević; Peter Gass; Dragana Filipović
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-05-04       Impact factor: 5.270

Review 9.  Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.

Authors:  Mohammad M Khan
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

10.  Aging changes and medical complexity in late-life bipolar disorder: emerging research findings that may help advance care.

Authors:  Martha Sajatovic; Brent P Forester; Ariel Gildengers; Benoit H Mulsant
Journal:  Neuropsychiatry (London)       Date:  2013-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.